ArticleNature cancer2021
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma.
Erratum issued Registry-linked trialOpen access · greenAbstract read
In one paragraph
Article in Nature cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT07422896 (A Phase I First-in-human Trial of Bvax), which is not on this map. Cited by 83 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
83citing papers in PubMed, 2 pooled it
11.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07422896 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation
A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma
Who cites it
83 citing papers in PubMed, 2 syntheses or guidelines pooled it, 112 citations in OpenAlex.
- ERK1/2 Phosphorylation Predicts Survival in Recurrent Glioblastoma Following Intracerebral and Adjuvant PD-1/CTLA-4 Immunotherapy: A REMARK-guided Analysis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Pooled it
- Impact of molecular and clinical variables on survival outcome with immunotherapy for glioblastoma patients: A systematic review and meta-analysis.CNS neuroscience & therapeutics · 2022Pooled it
- A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.Journal of neuro-oncology · 2026Trial
- MAPK-driven glioma progression and reprogramming of the tumor-associated immune response.Neuro-oncology · 2026Article
- Phase I Evaluation of Patients with Newly Diagnosed Glioblastoma Treated with Radiation, Nivolumab, and IDO1 Enzyme Inhibitor BMS-986205.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- IL6 Supports Development of an Immunosuppressive Microenvironment and Resistance to Therapy in Glioblastoma.Cancer research · 2026Article
- The role and mechanism of tubulin folding cofactor B in glioblastoma migration.Cell death discovery · 2026Article
- Glioma-intrinsic MAPK/ERK signaling promotes immunotherapy efficacy through T cell infiltration and interferon responses.Nature communications · 2026Article
- Invasion/metastasis-related differentially methylated genes predict prognosis in diffuse gliomas.Journal of neuro-oncology · 2026Article
- Tumor transcriptional state predicts survival in immune-checkpoint-blockade-treated glioblastoma.Nature cancer · 2026Article
- Immune Subtypes and Survival in Patients with Primary Glioma.medRxiv : the preprint server for health sciences · 2026Article
- Article
- Integrated immune profiling of chordomas reveals spatially organized niches and functional heterogeneity.Neuro-oncology · 2026Article
- A human tumor-immune organoid model of glioblastoma.Cell reports · 2026Article
- Biomarkers for predicting immunotherapy response and resistance in glioblastoma.Frontiers in immunology · 2026Review
- Dynamic release of extracellular particles after opening of the blood-brain barrier predicts glioblastoma susceptibility to paclitaxel.Nature communications · 2025Article
- Glioblastoma insights: Focus on crosstalk with the suppressive tumor microenvironment and advanced therapeutic strategies.Medicine · 2025Review
- Amlodipine exerts inhibitory effects against glioma stem cells through degrading EGFR and down-regulating its downstream pro-survival pathways.Cell death discovery · 2025Article
- Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.The Journal of clinical investigation · 2025Article
- Newly diagnosed glioblastoma IDHwt patients treated with radiation, nivolumab, and BMS-986205.Research square · 2025Article
23 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
42 authors at 6 institutions in 3 countries.
Víctor A Arrieta *Department of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Andrew X Chen *Program for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA.
J Robert KaneDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Seong Jae KangDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Cynthia KassabDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Crismita DmelloDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Junfei ZhaoProgram for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA.
Kirsten B BurdettDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Pavan S UpadhyayulaDepartment of Neurosurgery, Columbia University, New York, NY, USA.
Catalina Lee-ChangDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Joseph ShilatiDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Dinesh JaishankarRobert Lurie Comprehensive Cancer Center and Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Li ChenDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Andrew GouldDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Daniel ZhangDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-9962-9295
Jinzhou YuanDepartment of Biomedical Informatics, Columbia University, New York, NY, USA.
Wenting ZhaoDepartment of Biomedical Informatics, Columbia University, New York, NY, USA.
Xiaoyang LingDepartment of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jared K BurksDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-6173-9074
Brice LaffleurINSERM U1236, University of Rennes 1, Etablissement Français du Sang, Rennes, France.ORCID http://orcid.org/0000-0003-2904-9345
Christina AmideiDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Jeffrey N BruceDepartment of Neurosurgery, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0002-6844-0286
Rimas V LukasDepartment of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Jonathan T YamaguchiDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
David CieremansDepartment of Neurology, Columbia University, Vagelos College of Physicians and Surgeons Columbia University Irving Medical Center, New York, NY, USA.
Gerson RothschildDepartment of Microbiology and Immunology, Columbia University, New York, NY, USA.
Uttiya BasuDepartment of Microbiology and Immunology, Columbia University, New York, NY, USA.ORCID http://orcid.org/0000-0002-0185-7052
Matthew McCordDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Daniel J BratDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Hui ZhangDepartment of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Lee A D CooperDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-3504-4965
Bin ZhangDivision of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Peter SimsDepartment of Biomedical Informatics, Columbia University, New York, NY, USA.
Tim F CloughesyDepartment of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-8656-7483
Robert PrinsDepartment of Medical and Molecular Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-6282-6583
Peter CanollDepartment of Pathology and Cell Biology, Columbia University, New York, NY, USA.
Roger StuppDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Amy B HeimbergerDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID http://orcid.org/0000-0002-9970-8695
Craig HorbinskiDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.ORCID http://orcid.org/0000-0001-8340-9992
Fabio M IwamotoDepartment of Neurology, Columbia University, Vagelos College of Physicians and Surgeons Columbia University Irving Medical Center, New York, NY, USA. fi2146@cumc.columbia.edu.ORCID http://orcid.org/0000-0003-1397-9927
Raul RabadanProgram for Mathematical Genomics, Department of Systems Biology, Columbia University, New York, NY, USA. rr2579@cumc.columbia.edu.ORCID http://orcid.org/0000-0001-7946-9255
Adam M SonabendDepartment of Neurosurgery, Lou and Jean Malnati Brain Tumor Institute, Robert H Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. adam.sonabend@northwestern.edu.ORCID http://orcid.org/0000-0002-8347-1945
Northwestern University · USColumbia University · USThe University of Texas MD Anderson Cancer Center · USColumbia University Irving Medical Center · USUniversity of California, Los Angeles · USInserm · FR
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MTumor Environment and Metastasis (TEAM) Research ProgramP30CA060553 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Daniela E Matei · 1993 to 2026
$153.9MUCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007367 · NIGMS · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI REINER, STEVEN L · 1985 to 2021
$25.1MSTINGing GBM: A First-in- Man Clinical Trial in Surgical Resectable Recurrent GBMP50CA221747 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Pouya Jamshidi · 2018 to 2026
$21.4MSystematic pharmacological targeting of the core mechanisms responsible for maintaining cancer cell stateU54CA209997 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA, HONIG, BARRY H · 2016 to 2021
$10.9MTopology of Cancer Evolution and HeterogeneityU54CA193313 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI IAVARONE, ANTONIO, RABADAN, RAUL · 2015 to 2020
$10.4MRole of ncRNA Surveillance Complex "RNA Exosome" in Class Switch Recombination and Somatic HypermutationR01AI099195 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Uttiya Basu · 2012 to 2026
$9.8MNorthwestern University Skin Disease Research Center Resource-based CenterP30AR075049 · NIAMS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI Amy S Paller · 2019 to 2026
$6.6MTowards a quantitative understanding of tumor evolutionR35CA253126 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Raul Rabadan · 2021 to 2026
$5.6MLong noncoding RNA expressing genomic element that control antibody diversification and chromosomal integrity in B cellsR01AI134988 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Uttiya Basu · 2018 to 2026
$4.7MModulation of Microglia and T Cell Interactions in Malignant GliomaR01CA120813 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HEIMBERGER, AMY BETH, RAO, GANESH · 2007 to 2025
$4.7MNCI NIH HHS P30 CA016672NCI NIH HHS P30 CA060553NCI NIH HHS P50 CA211015NCI NIH HHS P50 CA221747NCI NIH HHS R01 CA120813NCI NIH HHS R35 CA253126NCI NIH HHS R50 CA243707NCI NIH HHS U54 CA193313NCI NIH HHS U54 CA209997NIAID NIH HHS R01 AI099195NIAID NIH HHS R01 AI134988NIAMS NIH HHS P30 AR075049NIGMS NIH HHS T32 GM007367NIH HHS DP5 OD021356NINDS NIH HHS R01 NS110703
Abstract
Only a subset of recurrent glioblastoma (rGBM) responds to anti-PD-1 immunotherapy. Previously, we reported enrichment of BRAF/PTPN11 mutations in 30% of rGBM that responded to PD-1 blockade. Given that BRAF and PTPN11 promote MAPK/ERK signaling, we investigated whether activation of this pathway is associated with response to PD-1 inhibitors in rGBM, including patients that do not harbor BRAF/PTPN11 mutations. Here we show that immunohistochemistry for ERK1/2 phosphorylation (p-ERK), a marker of MAPK/ERK pathway activation, is predictive of overall survival following adjuvant PD-1 blockade in two independent rGBM patient cohorts. Single-cell RNA-sequencing and multiplex immunofluorescence analyses revealed that p-ERK was mainly localized in tumor cells and that high-p-ERK GBMs contained tumor-infiltrating myeloid cells and microglia with elevated expression of MHC class II and associated genes. These findings indicate that ERK1/2 activation in rGBM is predictive of response to PD-1 blockade and is associated with a distinct myeloid cell phenotype.
Indexed as
GlioblastomaHumansImmunotherapyMAP Kinase Signaling SystemNeoplasm Recurrence, LocalPhosphorylation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
NCT07422896ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.